Abstract PS2-11-14: Residual disease after trastuzumab deruxtecan treatment of HER2+ breast tumors is promoted by leucyl tRNA synthetase 2 (LARS2) in HER2-low tumor cells
Year: 2026
Type: conference-abstract
Source: Clinical Cancer Research
Authors: V. Kurisetty, M. Homsi, S. Kabraji
Institution: Roswell Park Comprehensive Cancer Center
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7129303310
Cites:
Cited by:
Related to: